Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  3/13/2012
Rush University Medical Center
mi
from
Chicago, IL
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 3/13/2012
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  3/13/2012
Montefiore Medical Center
mi
from
Bronx, NY
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 3/13/2012
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  3/13/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 3/13/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  3/13/2012
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 3/13/2012
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  3/13/2012
Sarah Cannon Research Institute
mi
from
Nashville, TN
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 3/13/2012
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter on the Incidence of Auto-Pleurodesis in Patients With Malignant Pleural Effusions
Status: Enrolling
Updated:  3/26/2012
National Jewish Medical Center
mi
from
Denver, CO
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter on the Incidence of Auto-Pleurodesis in Patients With Malignant Pleural Effusions
Status: Enrolling
Updated: 3/26/2012
National Jewish Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter on the Incidence of Auto-Pleurodesis in Patients With Malignant Pleural Effusions
Status: Enrolling
Updated:  3/26/2012
Johns Hopkins University
mi
from
Baltimore, MD
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter on the Incidence of Auto-Pleurodesis in Patients With Malignant Pleural Effusions
Status: Enrolling
Updated: 3/26/2012
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter on the Incidence of Auto-Pleurodesis in Patients With Malignant Pleural Effusions
Status: Enrolling
Updated:  3/26/2012
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter on the Incidence of Auto-Pleurodesis in Patients With Malignant Pleural Effusions
Status: Enrolling
Updated: 3/26/2012
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter on the Incidence of Auto-Pleurodesis in Patients With Malignant Pleural Effusions
Status: Enrolling
Updated:  3/26/2012
Lahey Clinic
mi
from
Burlington, MA
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter on the Incidence of Auto-Pleurodesis in Patients With Malignant Pleural Effusions
Status: Enrolling
Updated: 3/26/2012
Lahey Clinic
mi
from
Burlington, MA
Click here to add this to my saved trials
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter on the Incidence of Auto-Pleurodesis in Patients With Malignant Pleural Effusions
Status: Enrolling
Updated:  3/26/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter on the Incidence of Auto-Pleurodesis in Patients With Malignant Pleural Effusions
Status: Enrolling
Updated: 3/26/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter on the Incidence of Auto-Pleurodesis in Patients With Malignant Pleural Effusions
Status: Enrolling
Updated:  3/26/2012
University of Utah
mi
from
Salt Lake City, UT
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter on the Incidence of Auto-Pleurodesis in Patients With Malignant Pleural Effusions
Status: Enrolling
Updated: 3/26/2012
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Amino Acid Tracer (FACBC) Positron Emission Tomography for Lung Nodule
A Pilot Study of the Utility of the Novel Amino Acid Radiotracer Anti-[18 F]FACBC for the Noninvasive Imaging of Lung Nodules
Status: Archived
Updated:  3/27/2012
Emory University
mi
from
Atlanta, GA
Amino Acid Tracer (FACBC) Positron Emission Tomography for Lung Nodule
A Pilot Study of the Utility of the Novel Amino Acid Radiotracer Anti-[18 F]FACBC for the Noninvasive Imaging of Lung Nodules
Status: Archived
Updated: 3/27/2012
Emory University
mi
from
Atlanta, GA
Mindfulness Therapy for Individuals With Lung Cancer
Status: Enrolling
Updated:  3/27/2012
Michigan State University
mi
from
East Lansing, MI
Mindfulness Therapy for Individuals With Lung Cancer
Status: Enrolling
Updated: 3/27/2012
Michigan State University
mi
from
East Lansing, MI
Click here to add this to my saved trials
Mindfulness Therapy for Individuals With Lung Cancer
Status: Enrolling
Updated:  3/27/2012
Allegiance Health
mi
from
Jackson, MI
Mindfulness Therapy for Individuals With Lung Cancer
Status: Enrolling
Updated: 3/27/2012
Allegiance Health
mi
from
Jackson, MI
Click here to add this to my saved trials
Optical Coherence Tomography: An Adjunct to Flexible Bronchoscopy in the Diagnosis of Lung Cancer
Optical Coherence Tomography: An Adjunct to Flexible Bronchoscopy in the Diagnosis of Lung Cancer
Status: Enrolling
Updated:  4/5/2012
OU Health Sciences Center
mi
from
Oklahoma City, OK
Optical Coherence Tomography: An Adjunct to Flexible Bronchoscopy in the Diagnosis of Lung Cancer
Optical Coherence Tomography: An Adjunct to Flexible Bronchoscopy in the Diagnosis of Lung Cancer
Status: Enrolling
Updated: 4/5/2012
OU Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Non-Invasive Biomarkers For Early Detection Of Lung Cancers
NON-INVASIVE BIOMARKERS FOR EARLY DETECTION OF LUNG CANCERS: ELEMENT 1: NON-RANDOMIZED PHASE II EVALUATION AND VALIDATION IN NEWLY DIAGNOSED LUNG CANCER PATIENTS
Status: Enrolling
Updated:  4/18/2012
Baptist Cancer Institute, Baptist Medical Center
mi
from
Jacksonville, FL
Non-Invasive Biomarkers For Early Detection Of Lung Cancers
NON-INVASIVE BIOMARKERS FOR EARLY DETECTION OF LUNG CANCERS: ELEMENT 1: NON-RANDOMIZED PHASE II EVALUATION AND VALIDATION IN NEWLY DIAGNOSED LUNG CANCER PATIENTS
Status: Enrolling
Updated: 4/18/2012
Baptist Cancer Institute, Baptist Medical Center
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Lapatinib and Cetuximab in Patients With Solid Tumors
A Phase I Study of Lapatinib and Cetuximab in Patients With Solid Tumors
Status: Enrolling
Updated:  5/14/2012
Georgetown University Medical Center
mi
from
Washington,
Lapatinib and Cetuximab in Patients With Solid Tumors
A Phase I Study of Lapatinib and Cetuximab in Patients With Solid Tumors
Status: Enrolling
Updated: 5/14/2012
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer
Phase I Feasibility Study of the Combination of Fondaparinux (Arixtra) With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  5/23/2012
University of Alabama at Birmingham
mi
from
Birmingham, AL
Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer
Phase I Feasibility Study of the Combination of Fondaparinux (Arixtra) With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 5/23/2012
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
Status: Enrolling
Updated:  6/18/2012
Medical Oncology Hematology, Stamford Hospital
mi
from
Stamford, CT
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
Status: Enrolling
Updated: 6/18/2012
Medical Oncology Hematology, Stamford Hospital
mi
from
Stamford, CT
Click here to add this to my saved trials
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
Status: Enrolling
Updated:  6/18/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
Status: Enrolling
Updated: 6/18/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
Status: Enrolling
Updated:  6/18/2012
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
Status: Enrolling
Updated: 6/18/2012
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
The Role of Audiovisual Biofeedback on Image Quality During 4D Anatomic and Functional Imaging
Investigating the Role of Audiovisual Biofeedback on Image Quality During 4D Anatomic and Functional Imaging
Status: Enrolling
Updated:  7/5/2012
Stanford University School of Medicine
mi
from
Stanford, CA
The Role of Audiovisual Biofeedback on Image Quality During 4D Anatomic and Functional Imaging
Investigating the Role of Audiovisual Biofeedback on Image Quality During 4D Anatomic and Functional Imaging
Status: Enrolling
Updated: 7/5/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Arizona Cancer Center, University of Arizona
mi
from
Tucson, AZ
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Arizona Cancer Center, University of Arizona
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Genesis Cancer Center
mi
from
Hot Springs, AR
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Genesis Cancer Center
mi
from
Hot Springs, AR
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
City of Hope National Medical Center
mi
from
Duarte, CA
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
UCLA Health System
mi
from
Santa Monica, CA
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
UCLA Health System
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Rush University Medical Center
mi
from
Chicago, IL
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
University of Chicago Medical Center
mi
from
Chicago, IL
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Massachusetts General Hospital
mi
from
Boston, MA
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Nevada Cancer Institute
mi
from
Las Vegas, NV
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Nevada Cancer Institute
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Hackensack University Medical Center
mi
from
Hackensack, NJ
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
University of North Carolina Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
University of North Carolina Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Piedmont Hematology Oncology Associates PA
mi
from
Winston Salem, NC
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Piedmont Hematology Oncology Associates PA
mi
from
Winston Salem, NC
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Oregon Health and Science University
mi
from
Portland, OR
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Penn State Hershey Cancer Institute
mi
from
Hershey, PA
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Penn State Hershey Cancer Institute
mi
from
Hershey, PA
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
U.T. Southwestern Medical Center
mi
from
Dallas, TX
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Swedish Medical Center
mi
from
Seattle, WA
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
BKM120 in Cancers With PIK3CA Activating Mutations
An Open Label, Phase II Trial of BKM120 in Cancers With PIK3CA Activating Mutations
Status: Enrolling
Updated:  7/12/2012
Massachusetts General Hospital
mi
from
Boston, MA
BKM120 in Cancers With PIK3CA Activating Mutations
An Open Label, Phase II Trial of BKM120 in Cancers With PIK3CA Activating Mutations
Status: Enrolling
Updated: 7/12/2012
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Internet-Based Clinical Information and Blood Sample Collection From Patients With Non-Small Cell Lung Cancer Who Never Smoked Cigarettes
Survey and Blood Sample Collection for Patients With Lung Cancer Who Never Smoked Cigarettes
Status: Enrolling
Updated:  7/19/2012
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Internet-Based Clinical Information and Blood Sample Collection From Patients With Non-Small Cell Lung Cancer Who Never Smoked Cigarettes
Survey and Blood Sample Collection for Patients With Lung Cancer Who Never Smoked Cigarettes
Status: Enrolling
Updated: 7/19/2012
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Ironwood Cancer and Research Center
mi
from
Chandler, AZ
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Ironwood Cancer and Research Center
mi
from
Chandler, AZ
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Arizona Oncology Associates
mi
from
Tucson, AZ
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Arizona Oncology Associates
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
University of California, Irvine Medical Center
mi
from
Orange, CA
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
University of California, Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
PMK Medical Group, Inc.
mi
from
Oxnard, CA
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
PMK Medical Group, Inc.
mi
from
Oxnard, CA
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Wilshire Oncology Medical Group, Inc.
mi
from
Pomona, CA
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Wilshire Oncology Medical Group, Inc.
mi
from
Pomona, CA
Click here to add this to my saved trials